RecruitingNCT07107607
Assessing Claims of Cannabis as an Anti-cancer Agent (CATA)
Cannabis as an Anti-cancer Agent: A Review of Medical Records in Patients With Cancer to Assess Potential Anti-cancer Benefits From Using Cannabis
Sponsor
HealthPartners Institute
Enrollment
50 participants
Start Date
Mar 19, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of the study is to find out how cannabis may help control cancer growth by reviewing medical records of patients who report cannabis helped treat their cancer.
Eligibility
Inclusion Criteria3
- diagnosed with cancer
- have used any type of cannabis/marijuana, including those with cannabidiol (CBD) and/or tetrahydrocannabinol (THC) to treat their cancer
- believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker
Exclusion Criteria3
- does not have cancer
- has not used any type of cannabis/marijuana, including those with CBD and/or THC to treat their cancer
- does not believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07107607
Related Trials
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
NCT055881411 location
Patient-Centered Assessment of Symptoms and Outcomes
NCT039526241 location
Tumor Related Epilepsy
NCT026393251 location
Improving Engagement in HIV and Cancer Care in Zimbabwe
NCT069343691 location
Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors
NCT074543307 locations